194 related articles for article (PubMed ID: 20232355)
1. Antagonists of growth hormone-releasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells.
Siejka A; Schally AV; Block NL; Barabutis N
Prostate; 2010 Jul; 70(10):1087-93. PubMed ID: 20232355
[TBL] [Abstract][Full Text] [Related]
2. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia.
Rick FG; Schally AV; Block NL; Nadji M; Szepeshazi K; Zarandi M; Vidaurre I; Perez R; Halmos G; Szalontay L
Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3755-60. PubMed ID: 21321192
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.
Rick FG; Schally AV; Block NL; Abi-Chaker A; Krishan A; Szalontay L
Prostate; 2013 Jun; 73(8):873-83. PubMed ID: 23280565
[TBL] [Abstract][Full Text] [Related]
4. Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
Klukovits A; Schally AV; Szalontay L; Vidaurre I; Papadia A; Zarandi M; Varga JL; Block NL; Halmos G
Cancer; 2012 Feb; 118(3):670-80. PubMed ID: 21751186
[TBL] [Abstract][Full Text] [Related]
5. The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines.
Pozsgai E; Schally AV; Hocsak E; Zarandi M; Rick F; Bellyei S
Int J Oncol; 2011 Oct; 39(4):1025-32. PubMed ID: 21701777
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone-releasing hormone antagonists reduce prostatic enlargement and inflammation in carrageenan-induced chronic prostatitis.
Popovics P; Cai R; Sha W; Rick FG; Schally AV
Prostate; 2018 Sep; 78(13):970-980. PubMed ID: 29786867
[TBL] [Abstract][Full Text] [Related]
7. Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanisms of action.
Kovacs M; Zarándi M; Halmos G; Groot K; Schally AV
Endocrinology; 1996 Dec; 137(12):5364-9. PubMed ID: 8940358
[TBL] [Abstract][Full Text] [Related]
8. Effects of antagonists of growth hormone-releasing hormone (GHRH) on GH and insulin-like growth factor I levels in transgenic mice overexpressing the human GHRH gene, an animal model of acromegaly.
Kovacs M; Kineman RD; Schally AV; Zarandi M; Groot K; Frohman LA
Endocrinology; 1997 Nov; 138(11):4536-42. PubMed ID: 9348175
[TBL] [Abstract][Full Text] [Related]
9. Antagonists of growth hormone-releasing hormone inhibit proliferation induced by inflammation in prostatic epithelial cells.
Popovics P; Schally AV; Salgueiro L; Kovacs K; Rick FG
Proc Natl Acad Sci U S A; 2017 Feb; 114(6):1359-1364. PubMed ID: 28123062
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
[TBL] [Abstract][Full Text] [Related]
11. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
Rick FG; Szalontay L; Schally AV; Block NL; Nadji M; Szepeshazi K; Vidaurre I; Zarandi M; Kovacs M; Rekasi Z
J Urol; 2012 Apr; 187(4):1498-504. PubMed ID: 22341819
[TBL] [Abstract][Full Text] [Related]
12. Essential role of p21/waf1 in the mediation of the anti-proliferative effects of GHRH antagonist JMR-132.
Volakaki AA; Lafkas D; Kassi E; Schally AV; Papavassiliou AG; Kiaris H
J Mol Endocrinol; 2008 Nov; 41(5):389-92. PubMed ID: 18765563
[TBL] [Abstract][Full Text] [Related]
13. The effect of GHRH antagonists on human glioblastomas and their mechanism of action.
Pozsgai E; Schally AV; Zarandi M; Varga JL; Vidaurre I; Bellyei S
Int J Cancer; 2010 Nov; 127(10):2313-22. PubMed ID: 20162575
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.
Seitz S; Hohla F; Schally AV; Moder A; Engel JB; Horn F; Varga J; Zarandi M; Ortmann O; Köster F; Buchholz S
Oncol Rep; 2008 Nov; 20(5):1289-94. PubMed ID: 18949435
[TBL] [Abstract][Full Text] [Related]
15. Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.
Szalontay L; Schally AV; Popovics P; Vidaurre I; Krishan A; Zarandi M; Cai RZ; Klukovits A; Block NL; Rick FG
Cell Cycle; 2014; 13(17):2790-7. PubMed ID: 25486366
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of GHRH antagonists on human GH-secreting adenoma tissue.
Szalontay L; Benveniste RJ; Schally AV; Vidaurre I; Nadji M; Zarandi M; Block NL; Kovacs M
Neuroendocrinology; 2012; 96(1):81-8. PubMed ID: 22377963
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.
Papadia A; Schally AV; Halmos G; Varga JL; Seitz S; Buchholz S; Rick F; Zarandi M; Bellyei S; Treszl A; Szalontay L; Lucci JA
Horm Metab Res; 2011 Oct; 43(11):816-20. PubMed ID: 22009378
[TBL] [Abstract][Full Text] [Related]
18. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.
Zhao L; Yano T; Osuga Y; Nakagawa S; Oishi H; Wada-Hiraike O; Tang X; Yano N; Kugu K; Schally AV; Taketani Y
Int J Oncol; 2008 Mar; 32(3):593-601. PubMed ID: 18292936
[TBL] [Abstract][Full Text] [Related]
19. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
20. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases.
Rick FG; Schally AV; Szalontay L; Block NL; Szepeshazi K; Nadji M; Zarandi M; Hohla F; Buchholz S; Seitz S
Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1655-60. PubMed ID: 22307626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]